Hem/Onc Roundup: Smoking Cession and Lung Cancer Mortality, IUDs and Cervical Cancer, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved a new treatment combination for liver cancer, a study found that patients taking statins were less likely to have a melanoma recurrence, and more.

The FDA approved Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) for patients with hepatocellular carcinoma who previously received Nexavar® (sorafenib).

Patients taking statins prior to receiving a melanoma diagnosis have a decreased risk of a melanoma recurrence compared with those not taking statins, according to a study published in the British Journal of Dermatology.

Smoking cessation interventions in conjunction with existing lung cancer screening would reduce lung cancer mortality by 14% and increased life-years by 81%, according to a study published in the Journal of Thoracic Oncology.

Adults at high risk of liver cancer may lower their odds by taking low-dose aspirin, according to the results of study published in the New England Journal of Medicine.

In case you missed it, more hem/onc headlines are featured below: